Introduction
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is fatal if left untreated, meriting its designation as a medical emergency. 1, 2 In 2014, more than 3,000 people were diagnosed with AML in the UK, while around 2,500 patients died due to this condition. 3 Mortality occurs quickly and is often difficult to prevent. The 5-year survival rate is 26% in the US and 17% in the EU. 4 Treatment should therefore be initiated shortly after diagnosis, ideally within a matter of days. Even with timely intervention, not all patients achieve remission. As many as 50-70% of those who do achieve remission following chemotherapy relapse within 3 years. 5 Bone marrow failure is a defining characteristic of AML. Mortality results predominantly from complications associated with bone marrow failure, such as opportunistic infections or hemorrhage.
The treatment pathway for AML can be broken down into three phases: induction chemotherapy, consolidation chemotherapy, and stem cell transplantation (SCT) (Figure 1 ). Intensive induction chemotherapy is the standard of care for most patients with newly diagnosed AML, aimed at inducing complete remission (CR). 1 Should the patient achieve CR, they may continue consolidation chemotherapy or receive high-dose chemotherapy conditioning as a bridge to SCT. 1 Patients often do not reach remission and even if they do, they may still relapse, requiring alternative courses of therapy. 5 Likewise, successful treatment is not without difficulty: the chemotherapeutic agents used to treat this disease are associated with significant toxicities. 7 Even SCT is associated with considerable morbidity and mortality, given the high incidence of graft versus host disease (GVHD). 8 The diagnosis of AML may be very traumatic for a patient who is given little time to adjust before the initiation of aggressive therapy. In this scenario, short-term and long-term well-being are significantly impacted by the initial choice of therapy, ie, the current standard of care in AML management. 9, 10 Health-related quality of life (HRQoL) is a measurement of well-being. In one application, it is employed during clinical trials when the impact of an investigational treatment on QoL must be quantified. Clinical trials often consider overall survival or progression-free survival as a primary end point, with HRQoL as a secondary end point. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) is a frequently used, non-preference based, cancer-specific questionnaire that assesses HRQoL.
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For economic evaluation, many health technology assessment bodies require that effectiveness is expressed in terms of quality-adjusted life-years (QALYs). They also commonly prefer health state utility values (HSUVs) that are determined using the EuroQol five-dimensional (EQ-5D) patient preference questionnaire. [12] [13] [14] QALYs consider both the quantity of survival and its quality. In each disease setting, HSUVs are used to transform the time patients spend in different health states into QALYs.
The EQ-5D was designed to enable the application of cost-effectiveness analysis; patients contribute to definitions of health utility through population surveys and self-reported heath states. EQ-5D scores may then be translated into equivalent QALYs. 15, 16 Patients' preference for one health state over another, as in the EQ-5D scale, dictates their assigned value for that health state. However, the use of EQ-5D in cancer clinical trial data collection is not as widespread as the use of non-preference scales such as the QLQ-C30. The QLQ-C30 consists of 30 questions across five functional scales 11 Where data on health state utilities were not directly collected from patients in clinical trials, utility estimates may be "mapped" from condition-specific HRQoL scales, such as through an algorithmic technique described by Crott et al. [17] [18] Health state utilities for different stages of AML and the toxicities associated with each chemotherapy and SCT regimen are used during the health technology assessment process to estimate the incremental effectiveness of new products versus the standard of care. Most of the previously reported economic analyses have not utilized utilities to describe a range of health states within AML such as pre-relapse versus post-relapse; these studies did not consider the utilities by treatment stage (induction, consolidation, maintenance) or addressed some key health states such as transplantation. 19 This study aimed to review utility values that may be used in economic evaluations of AML. In the process, it aimed to illustrate and critically discuss challenges in creating a comprehensive set of utility values.
Materials and methods
A list of relevant health states based on the current consensus in AML treatment was selected and reviewed with UK-based clinical experts experienced in treating AML patients. The health states and their characteristics were defined as part of an unpublished time trade-off (TTO) study. The TTO approach, which seeks to determine the length of lifetime a person would hypothetically sacrifice in exchange for a better health state, has been widely used to obtain health state values. 20 In the initial stages of TTO process, health state descriptions were developed and validated in collaboration with key opinion leaders and other specialists.
Disease symptoms, adverse events in treatment, and treatment setting were considered as those that may influence the physical, functional, and emotional health of patients.
Relevant health states identified are as follows ( Figure 1 ):
• Newly diagnosed and undergoing induction treatment Table S1 .
If no studies were identified with data on a specific health state in AML, additional targeted searches were performed to locate studies reporting either utilities or HRQoL related to that specific health state, using a condition that most closely mimics the clinical picture of AML.
Articles were included in the review if they reported utility values for one of the identified health states. Cost effectiveness analyses and health technology assessments were included if utility values were reported. Studies that did not have AML populations and those not reporting utility values were excluded. Only publications written in English and published starting from January 2006 were considered.
Shortlisted articles were initially assessed based on title and abstract. Publications not meeting inclusion criteria were excluded and listed along with the reason for study exclusion. Full-text publications were then retrieved and assessed based on the full text. All steps were conducted by two independent reviewers, and any discrepancies in article selection were reassessed by a third reviewer. After the full-text review, all papers meeting inclusion criteria were retained for data extraction. Papers that were excluded in each step were listed, along with their reason for exclusion. These methods were adapted from the procedure described by the York Centre for Reviews and Dissemination. 21 Inclusion and exclusion criteria for the systematic review are presented in Table 1 .
Health state utility derivations
Relevant HRQoL data (EORTC QLQ-C30) for patients undergoing SCT were mapped using a previously published algorithm to estimate EQ-5D scores from the EORTC QLQ-C30 scores on the following scales: physical functioning, emotional functioning, social functioning, constipation, diarrhea, pain, and sleep. 17, 18 The algorithm is based on an ordinary least-squares regression algorithm model, which was derived in patients with both the QLQ-C30 questionnaire and the EQ-5D instrument. 18 In this model, the dependent variable was the calculated overall EQ-5D utility decrement, and the explanatory variables were the calculated QLQ-C30 scores using the following formula: In studies where QLQ-C30 values were already mapped to the EQ-5D, the EQ-5D values were utilized.
Results
The literature search identified 1398 records (Figure 2) . A total of 284 full-text articles were retrieved, with 11 of those meeting all inclusion criteria.
The characteristics of the 11 studies are shown in Table 2 . 19, 22, [24] [25] [26] [27] [28] [29] [30] 32 Nine studies reported utility values for relevant health states. No studies were identified that reported utility values for patients undergoing SCT treatment. Thus, a targeted search revealed two studies that reported HRQoL (QLQ-C30) for patients undergoing SCT. These were included, with HRQoL data mapped to EQ-5D values as previously described. 25, 31 Table 3 presents the collated utility values, their corresponding AML-relevant health state, and methods of data collection extracted from each study. Many studies measured utility values using the EQ-5D, others employed the QLQ-C30 and mapping or their utilities were assumptions based on studies of similar conditions, and two studies incorporated utilities based on TTO studies. Although there was some variability in the utilities for each health state, they were relatively similar across the identified studies. The lowest utility values were seen in newly diagnosed patients undergoing induction treatment (range 0.524-0.67) and patients in relapse (range 0.50-0.53). Utility values for patients in remission post-chemotherapy ranged from 0.81 to 0.91, while values for patients post-SCT ranged from 0.71 to 0.83. Factors The utility values can be used in economic models following the AML treatment pathway. Figure 3 illustrates the fluctuation of utility values as they are matched to each health state in the pathway.
Discussion
Most of the studies utilized data that were collected directly from patients through the EQ-5D questionnaire or the QLQ-C30 questionnaire. Extrapolation of utilities from other diseases to AML was done for SCT health states (remission and relapse), which identified an area of future research to determine these utilities directly from patients with AML. Based on discussions with the UK-based AML experts, it appears that the utility estimates of the current knowledge base may be fairly representative of health states experienced by AML patients, barring larger and wider-ranging studies on AML utilities in different health states.
The utility values collated show variations in utility across the various health states in AML, with the worst values assigned to both induction and relapse. This finding appears to connote a similarly poor QoL for active AML disease, whether at the beginning of treatment or return of the disease. These low HSUVs in both forms of active AML disease are consistent with findings of a similar systematic review. 34 More importantly, this stresses the need to focus efforts both on disease reduction and improvement of QoL among patients with active disease.
The transition stage between active disease and remission, ie, the treatment phase, had higher utility values than active disease, which is to be expected given the goal of therapy to reduce disease burden. The values during this stage reflect the complications and side effects that may occur from the therapy itself. 35, 36 This finding is consistent with previous studies on the effect of treatment on both the QoL and functional status of patients with AML. 37 The persistent deficits in utility values even during remission also illustrate how patients perceive their own well-being during this health state. 38 As for utility values that exceeded those of the general population, in a TTO approach respondents are not asked to compare their health state to the normal population, but instead to compare their health to the perfect health (utility of 1). As such, the resultant values cannot be compared to the general population. Furthermore, utility scores reported by patients are based on their own individual evaluation of QoL. Thus, patients in remission may report much higher utility scores compared to their diseased health state. The contrast in their QoL between these two health states may lead them to overestimate the QoL of their health state in remission.
EQ-5D utility may depend on the value set used, especially for severe health states. Unfortunately, the identified studies did not report the value sets used in the analyses, which may add uncertainty to the results. Additionally, utility values mapped from the QLQ-C30 instrument should be used with caution because of the derivative nature of the values generated. 37 While the validity of mapping techniques has been tested against EQ-5D and other preference-based instruments, such as short form 6 dimensions (SF-6D) and 15 dimensions (SF-15D), it is important to note that primary data for utilities taken directly from patients would still hold priority over these derived values. 38, 39 As experience grows with the use of these instruments and their mapping into QALYs, studies collating and validating this application may be beneficial for future economic analyses, especially when there is a lack of primary studies on utilities focusing on particular diseases such as AML. [39] [40] [41] [42] In our selection of final utility values recommended for use in health economic evaluations, we prioritized values collected directly from patients to those mapped. We, how- ever, made an exception for the utility values related to SCT. Although Kurosawa et al's publication reported EQ-5D values collected directly from patients, the validity of this research is diminished since it was never published in a peer-reviewed journal. 22 Furthermore, the values reported by Kurosawa et al were considerably lower as compared to other studies, such as those of Uyl-de Groot et al and Leunis et al. 31, 24 On the other hand, the mapped values using Grulke et al for remission prior to SCT were more consistent with values reported by other studies. 27 The consistently lower HSUVs reported in the Kurosawa et al's study compared to other studies is the basis for the selection of the HSUVs mapped from Grulke et al. Although the use of mapping applied to mean values versus individual patient level adds potential weakness to resultant utility values, the HSUVs derived from Grulke et al provided a more clinically plausible progression in the improvement of QoL with successful treatment (ie, with SCT), as depicted in Figure 3 . Selecting the HSUV provided by Kurosawa et al would have portrayed a significant decline in HSUV following SCT not compatible with known clinical course and prognosis of patients in that health state. 7, [43] [44] [45] [46] Overall, this study uncovered a common issue when searching for utility values for rare diseases, such as AML. Studies on rare diseases are relatively rare in themselves and require considerable resources to find. 47 In this study, only 11 have met the inclusion criteria, with many studies excluded mainly because they did not deal with acute hematologic malignancy, and because they did not examine QoL or utility outcomes. One recommendation is to institute a comprehensive policy covering the registration and monitoring of the health status of patients with rare diseases, including their treatment regimens, clinical outcomes, and QoL. 48 With such broad remit, multiple studies may be generated from these datasets and registries, so-called "real-world evidence", enabling the creation of a more complete picture of the disease process, its treatment, and experience living with the disease. TTO studies may likewise be performed to extract further information from existing registries and research. 9, 49, 50 More importantly, the determination of HSUVs for rare diseases is particularly challenging, especially since the populations used may be smaller than usual (resulting in wider ranges) and the methodology of determining HSUVs may vary considerably as well. 50 Establishing a set of recommendations to standardize HSUV determination across different diseases and contexts may be valuable in the long term.
Conclusion
Here we present a broad summary of the available utility scores in AML. There are relatively few methodologically robust HSUVs that can be directly used in economic evaluations concerned with AML. Careful interpretation of published values is advised considering significant differences in methodologies as well as patient population inclusion and size. There is a need to develop new HSUVs with larger-sized studies which improve on those currently available, either by utilizing TTO studies or by making greater use of conditionspecific data and further use of mapping algorithms.
